Strata Critical Medical (SRTA) Earnings Date & Reports

Key Takeaways

• Total revenue rose 50.3% year over year to $74.1 million, ahead of analyst consensus estimates.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) more than doubled to $9.6 million, with margin expanding to 13.0%.
• Free cash flow reached a record $8.6 million, highlighting the company's improving cash-generation profile.
• GAAP (Generally Accepted Accounting Principles) earnings per share (EPS) came in at a loss of $0.09, below the consensus estimate of a $0.01 loss, due to non-cash items.
• Management reiterated full-year 2026 guidance and announced a new $20 million share repurchase authorization.
• For additional detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover Trending AI Robots for AI-driven trading signals and ideas.

Earnings Context and Why It Matters

Strata Critical Medical (SRTA), formerly Blade Air Mobility, operates time-critical logistics and clinical services for the organ transplant ecosystem across the United States. Its third quarter, ended September 30, 2026, marks roughly one year since the company's strategic transformation and rebranding following the sale of its passenger aviation business. This report matters because it offers the clearest signal yet on whether Strata's integrated organ recovery, perfusion, and logistics platform can convert rapid revenue growth into durable margins and cash flow. With a seasonally soft transplant quarter pressuring logistics volumes, investors were watching closely to see whether clinical segment share gains and expense discipline could offset that headwind and keep full-year guidance intact.

Reported Results

Strata reported total revenue of $74.1 million for its third quarter of fiscal 2026, an increase of 50.3% from $49.3 million in the prior-year period and above consensus estimates. Growth was driven by the Clinical segment, where revenue climbed to $29.2 million from $2.8 million a year earlier, reflecting recent acquisitions and organic share gains. Logistics revenue declined 3.5% year over year to $44.9 million amid seasonal transplant volume declines and shorter industry-wide trip distances.

Gross profit rose 57.9% to $16.8 million, with gross margin expanding 110 basis points to 22.7%. Adjusted EBITDA jumped to $9.6 million from $4.2 million a year earlier, and adjusted EBITDA margin reached 13.0% versus 8.5% in the prior-year quarter. Operating cash flow was $9.5 million, and free cash flow hit a record $8.6 million.

On a GAAP basis, the company posted a net loss from continuing operations of $7.6 million, or $0.09 per share, compared with the consensus estimate of a $0.01 loss. Management attributed the loss entirely to non-cash, transaction-related items, including $5.5 million of intangible asset amortization, a $2.6 million fair-value adjustment on acquisition earnouts, and a $1.3 million realized loss on the sale of Joby Aviation shares received from the passenger business divestiture.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those looking to apply a data-driven approach to names like SRTA, exploring the AI Screener can be a useful starting point.

Market Reaction and Investor Sentiment

Investor reaction to the report leaned positive in early trading, with shares moving higher in pre-market action on the morning of the release. The initial response reflected a focus on the quarter's operational strengths rather than the headline GAAP loss, which management framed as the result of non-cash items tied to acquisitions and the passenger business divestiture. The record free cash flow figure, the rebound in logistics gross margin to 20.8%, and the newly announced buyback were seen as evidence of improving capital efficiency. Still, the EPS miss relative to consensus and softer logistics revenue kept some caution in place, with the central question for investors being whether clinical growth and margin gains can outrun pressure on the company's largest segment.

Forward Outlook and Key Factors to Monitor

Management reiterated its full-year 2026 guidance, calling for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million, and free cash flow before aircraft and engine acquisitions of $15 million to $22 million. The midpoint implies a low single-digit sequential revenue increase in the fourth quarter, with growth expected to be led primarily by the Clinical segment while logistics stays roughly flat.

Investors should watch several items in the quarters ahead. First, clinical gross margin slipped to 25.6% as the company invested in staffing and training; management expects that figure to improve into 2027 as part-time providers are replaced with dedicated resources. Second, industry transplant volumes had not yet shown their typical seasonal rebound early in the fourth quarter, so the pace of recovery will be a key signal for logistics demand.

Longer term, Strata continues to expect 2027 growth to be driven by its Clinical division, supported by rising adoption of normothermic regional perfusion (NRP), a technique used to preserve donor organs, and third-party surgical recovery. The company also flagged a new cardiothoracic surgical staffing line and an additional $27.5 million in potential passenger-sale consideration due by early 2027. The timing and execution of mergers and acquisitions (M&A), alongside deployment of the $20 million buyback, remain areas for investors to monitor, though no price predictions or investment advice are implied.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations